Type of Hodgkin's lymphoma-Classical Hodgkin's lymphma Posts on Medivizor
Navigation Menu

Type of Hodgkin’s lymphoma-Classical Hodgkin’s lymphma Posts on Medivizor

Have outcomes improved for patients with Hodgkin’s lymphoma who relapse after a stem cell transplant?

Posted by on Mar 16, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of patients with classical Hodgkin’s lymphoma (cHL) that came back after an autologous stem cell transplant (autoSCT). This study found that advancements in treatment have helped improve survival outcomes for patients. Some background Chemotherapy is usually the first-line...

Read More

Does omitting radiotherapy improve outcomes for patients with early-stage Hodgkin lymphoma?

Posted by on Mar 3, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of removing radiotherapy from treatment for patients with early-stage Hodgkin lymphoma (HL). This study concluded that radiotherapy improved survival without disease progression for patients while omitting it did not affect overall survival. Some background Chemotherapy followed by radiotherapy (RT)...

Read More

Can a stem cell transplant improve outcomes of patients with cHL after nivolumab treatment?

Posted by on Feb 29, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of a stem cell transplant after nivolumab (Opdivo) therapy in patients with classical Hodgkin’s lymphoma (cHL) that came back or stopped responding to treatment. This study concluded that nivolumab followed by stem cell transplant is safe and effective for these patients. Some background...

Read More

Reviewing outcomes for children and adolescents with Hodgkin’s lymphoma

Posted by on Feb 23, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This article reviewed treatments and outcomes for children and adolescents with Hodgkin’s lymphoma (HL). The authors found that chemotherapy alone was a common treatment and that outcomes have improved for these young patients. Some background Hodgkin’s lymphoma (HL) is a cancer of the white blood cells. It can affect both...

Read More

Evaluating ESHAO chemotherapy for patients with hard-to-treat Hodgkin’s lymphoma

Posted by on Jan 19, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of ESHAOx chemotherapy for patients with Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. This study found that this regimen is effective, with manageable side effects. Some background Most patients with HL respond well to initial treatment. However, some...

Read More

How effective is long-term brentuximab vedotin treatment for patients with recurrent or non-responding Hodgkin’s lymphoma?

Posted by on Jan 12, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated long-term treatment with brentuximab vedotin (Adcetris) for patients with Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. This study concluded that this treatment had a long-term benefit for some patients. Some background Most patients with HL respond well to initial treatment....

Read More

Evaluating immune-related side effects associated with pembrolizumab.

Posted by on Nov 29, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study wanted to find out what put patients at risk of having immune-related side effects when they were treated with pembrolizumab (Keytruda). The study found that patients with a higher body mass index (BMI; a measurement of weight in relation to height) and more cycles of treatment were more likely to determine immune-related side...

Read More

Can PET scanning help guide treatment for patients with Hodgkin’s lymphoma?

Posted by on Oct 13, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated whether PET scanning after chemotherapy might help predict outcomes and guide treatment for patients with early-stage Hodgkin's lymphoma (HL). This study found that PET scanning can help identify high-risk patients after chemotherapy. Some background Chemotherapy combined with radiotherapy is the standard of...

Read More

Is tislelizumab safe and effective for patients with relapsed or refractory classical Hodgkin’s lymphoma?

Posted by on Oct 12, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined how effective and safe tislelizumab (BGB-A317) is for patients with relapsed or refractory classical Hodgkin's lymphoma (cHL). The authors concluded that most patients responded to tislelizumab but also experienced side effects. Some background cHL is often treated with chemotherapy or stem cell...

Read More